The Pharma Letter1d
The week in pharma: action, reaction and insight – week to January 10
Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label ...
Taiwan News5d
60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
Physicians or patients who wish to participate in the 60 Degrees Pharmaceuticals Tafenoquine for Babesiosis Expanded Access clinical study are encouraged to visit the Company’s website for information ...
The Pharma Letter6d
FDA liver injury warning label for Agios' Pyrukynd
Administration (FDA) approved an update to the US Prescribing Information (USPI) for Pyrukynd (mitapivat) for the treatment ...